SCHEMBL2771305

SCHEMBL2771305

Nc1cccc2c1CCc1cccc3[nH]nc-2c13

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 3/20 0.57
MAPK9 P45984 3/20 0.57
MAPK10 P53779 2/20 0.57
KDR P35968 4/20 0.44
LCK P06239 3/20 0.44
CSF1R P07333 3/20 0.44
FGFR1 P11362 3/20 0.44
ROCK1 Q13464 3/20 0.44
DYRK1A Q13627 3/20 0.44
AURKA O14965 3/20 0.44
NPC1 O15118 3/20 0.44
KIT P10721 2/20 0.44
FLT3 P36888 2/20 0.44
PLK4 O00444 2/20 0.44
DAPK3 O43293 2/20 0.44
PRKD3 O94806 2/20 0.44
MAP4K4 O95819 2/20 0.44
NTRK1 P04629 2/20 0.44
CDK1 P06493 2/20 0.44
LYN P07948 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2769394 0.83 MAPK10 (0.76) MAPK8MAPK9MAPK10KDRLCK
SCHEMBL2768004 0.81 MAPK8 (0.52) MAPK8MAPK9MAPK10KDRLCK
SCHEMBL2768727 0.81 MAPK8 (0.52) MAPK8MAPK9MAPK10KDRLCK
SCHEMBL2768700 0.81 MAPK10 (0.52) MAPK8MAPK9MAPK10KDRLCK
SCHEMBL2768161 0.74 KDR (0.50) MAPK8MAPK9MAPK10KDRLCK
SCHEMBL2771632 0.73 MAPK8 (0.44) MAPK8MAPK9MAPK10KDRLCK
SCHEMBL2769418 0.72 ABL1 (0.46) MAPK8MAPK9MAPK10KDRLCK
SCHEMBL7946079 0.69 KDR (0.65) MAPK8MAPK9MAPK10KDRLCK
SCHEMBL20404268 0.67
SCHEMBL30060771 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-20060111419-A1 Novel fused indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-05-25 US disclosed
EP-1479670-A1 NOVEL FUSED RING INDAZOLE COMPOUNDS Eisai Co., Ltd. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111419-A1 Novel fused indazole compounds MAP2K3, MAP3K11, MAP2K2 MAPK8 38/4885MAPK9 42/4885MAPK10 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.